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Background: Asthma is a heterogeneous disease characterized by different clinical phenotypes 
and the involvement of multiple inflammatory pathways. During airway inflammation, many 
cytokines and chemokines are released and some are detectable in the sera.
Objective: Serum chemokines and cytokines, involved in airway inflammation in asthma 
patients, were investigated.
Methods: A total of 191 asthma patients were classified by hierarchical cluster analysis, includ-
ing the following parameters: forced expiratory volume in 1 second (FEV
1
), eosinophil cationic 
protein (ECP) serum levels, blood eosinophils, Junipers asthma symptom score, and the change in 
FEV
1
, ECP serum levels, and blood eosinophils after 3 weeks of asthma therapy. Serum proteins 
were measured by multiplex analysis. Receiver operating characteristic (ROC) curves were used 
to evaluate the validity of serum proteins for discriminating between asthma clusters.
Results: Classification of asthma patients identified one cluster with high ECP serum levels, 
increased blood eosinophils, low FEV
1
 values, and good FEV
1
 improvement in response to asthma 
therapy (n=60) and one cluster with low ECP serum levels, low numbers of blood eosinophils, 
higher FEV
1
 values, and no FEV
1
 improvement in response to asthma therapy (n=131). Serum 
interleukin (IL)-8, eotaxin, vascular endothelial growth factor (VEGF), cutaneous T-cell-attracting 
chemokine (CTACK), growth-related oncogene (GRO)-α, and hepatocyte growth factor (HGF) were 
significantly different between the two clusters of asthma patients. ROC analysis for serum proteins 
calculated a sensitivity of 55.9% and specificity of 75.8% for discriminating between them.
Conclusion: Serum cytokine and chemokine levels might be predictors for the severity of 
asthmatic inflammation, asthma control, and response to therapy, and therefore might be useful 
for treatment optimization.
Keywords: asthma, cluster, phenotype, serum cytokines
Introduction
Asthma is a chronic inflammatory disorder of the airways, characterized by reversible 
airflow obstruction, airway hyper-responsiveness, and typical clinical symptoms such as 
wheezing, breathlessness, and chest tightness as a result of inflammation in the airways. 
The heterogeneity of the clinical presentation of asthma patients suggests that different 
inflammatory pathways play a role in the pathogenesis of asthma.1 Many cell types, 
including immune cells and tissue cells, are involved in asthmatic inflammation, and 
several molecular and cellular pathways are activated for the release of chemokines and 
cytokines.2 In allergic asthma, allergen-specific T-helper (Th)-2 lymphocytes release 
interleukin (IL)-4, -9, and -13, which are essential for the production of allergen-specific 
immunoglobulin E (IgE).3 IgE binding on the high-affinity FC ε receptor 1 (FcεR1) 
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activates mast cells and eosinophils, which subsequently 
secrete inflammatory mediators.4 These mediators cause 
bronchial smooth muscle contraction and increase airway 
hyper-reactivity, a cardinal feature of asthma.5 Additionally, 
other effector T-cell subsets, like Th1 or Th17 cells, can 
contribute to airway inflammation.6 Th17 cells are thought 
to be mainly involved in rhinovirus-induced asthma7 and 
neutrophil recruitment to the airways,8 whereas Th1 cells are 
important for induction of apoptosis in tissue cells.9
The identification of inflammatory proteins that are 
specific for clinical asthma phenotypes is one important 
approach to facilitate the diagnosis, therapy, and monitoring 
of asthma. Recently, it was demonstrated that the presence 
of serum IL-8, vascular endothelial growth factor (VEGF), 
and metalloproteinase-9 was associated with diisocyanate-
induced asthma.10 In addition, increased IL-17 levels in 
sera of patients with severe asthma were described,11 and 
an association between serum IL-32 levels and treatment 
response in asthma patients was demonstrated.12 Moreover, 
differences in serum cytokine levels between allergic and 
non-allergic asthma have been demonstrated.13
In this study, we investigated serum and chemokine levels 
in 191 asthma patients who were classified into two groups 
according to several clinical and physiological parameters 
and the response to asthma therapy. Our hypotheses were 
that these two clinically different groups of asthma patients 
are characterized by different cytokine and chemokine serum 
levels and that the upregulation of cytokine and chemokine 
serum levels might indicate poorly controlled asthma.
Methods
study design
Adult patients had a physician diagnosis of asthma according 
to Global Strategy for Asthma Management and Prevention, 
Global Initiative for Asthma (GINA) guidelines.To exclude 
chronic obstructive pulmonary disease, asthma patients had to 
show a reversibility in forced expiratory volume in 1 second 
(FEV
1
) in response to a short-acting β2-agonist of at least 
12% predicted. Asthma patients with an acute respiratory 
infection were excluded. All asthma patients included in the 
study were admitted to, and treated for at least 3 weeks at, 
the high-altitude clinic Davos-Wolfgang, which is located 
1,600 m above sea level in the Swiss Alps. The patients were 
admitted for a rehabilitation and asthma treatment optimiza-
tion program and were treated according to the recent GINA 
guidelines; there were no acute  hospitalizations. All medica-
tions related to asthma treatment and changes to it during 
the stay in the high-altitude clinic are shown in Table 1. To 
Table 1 characterization of asthma patients
Parameters Cluster 1 Cluster 2 Unpaired t-test Pearson’s  
chi-squared test
Number
Allergic asthma 70.0% 80.2% 0.122 191
Age (years) 54.4±12.0 (21–79) 48.1±15.9 (18–80) 0.003 191
Age of onset (years) 23.2±17.5 (0–52) 24.2±16.8 (0–65) 0.718 191
sex (male) 43.3% 44.3% 0.903 191
smoker 5.0% 3.1% 0.506 191
Pack years 4.2±6.8 (0–30) 4.0±7.3 (0–35) 0.871 191
BMi (kg/m2) 24.8±4.1 (17.0–39.0) 25.7±3.8 (19.0–36.0) 0.129 191
ATs criteria 56.7% 18.3% ,0.001 191
exacerbations during  
last year
5.4±3.5 3.8±3.0 0.004 191
Asthma control (%) 191
 nc 71.7 32.1
 Pc 25.0 40.5
 Fc 3.3 27.5
Adherence to therapy 90.9% 93.4% 0.571 191
serum ige level (kU/l) 457.8±991.1 (0–5000) 620.8±2455.0 (0–26973) 0.516 190
long-acting β2 agonist 100% 89.3% 0.009 191
short-acting β2 agonist  
(puffs per day)
3.1±3.8 (0–20) 1.4±2.8 (0–20) 0.002 191
systemic steroids 43.3% 19.1% ,0.001 191
inhaled steroids 98.3% 93.1% 0.134 191
Theophylline 36.7% 15.3% 0.001 191
Notes: Asthma patients belonging to cluster 1 or 2 are characterized by indicated parameters. Percentages show the fraction of patients fulfilling indicated parameters/
characteristics. Age, Age of onset, Pack years, BMi, serum ige level and short-acting β2 agonist are presented as mean ± sD (range). Asthma exacerbation is presented as 
mean ± sD.
Abbreviations: ATs, American Thoracic society; BMi, body mass index; Fc, fully controlled; ige, immunoglobulin e; nc, not controlled; Pc, partly controlled.
Journal of Asthma and Allergy 2014:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
69
Differential serum protein markers and clinical severity of asthma
classify these patients as atopic or non-atopic, we evaluated 
their medical history, and skin prick tests were performed 
with animal dander, food allergens, pollens, fungi, and latex. 
The NIOX system (Aerocrine, Solna, Sweden) was used to 
measure fractional exhaled nitric oxide (NO) according to the 
manufacturer’s instructions. Blood eosinophils and eosinophil 
cationic protein (ECP) were analyzed in the laboratory of the 
high-altitude clinic. All clinical features and examinations 
were evaluated on the day that the patients arrived in the clinic 
(entry) and after 3 weeks (discharge) and are shown in Table 1. 
The multidisciplinary treatment at high altitude, consisting 
of personalized treatment plans with physiotherapy and edu-
cation, aimed to achieve full asthma control with the lowest 
possible dose of asthma medication. The six-item Asthma 
Control Questionnaire (Junipers symptom score) was used to 
assess the level of asthma control.14 Responses to each item 
were rated on a six-point scale; the mean was subsequently 
calculated and ranged between 0 (totally controlled) and 
6 (severely uncontrolled). Informed consent was obtained 
from all asthma patients. The study was approved by the local 
ethical committees of the Cantons of Grissons and Zürich. 
Data were stored in a database and analyzed using SPSS 17.0 
(SPSS Schweiz AG, Zürich, Switzerland) and Graphpad Prism 
4 (GraphPad Software, Inc., La Jolla, CA, USA).
statistical analysis and cluster formation
Because the total number of patients was limited to 191 in 
this study, we divided the asthma patients into two groups 
by hierarchical cluster analysis. Power analysis calculated 
a total sample size of 59 patients for each group (effect 
size =0.4, α=0.05, 1 – β =0.95). Pearson’s chi-squared 
test was used for statistical analyses of categorical vari-
ables because the datasets in each cluster were large 
enough and the values of cluster 1 and 2 are independent. 
Mann–Whitney U test was used for statistical analyses of 
cytokine concentrations because they were not normally 
distributed. Multiple testing correction was performed 
by the Benjamini and Hochberg false discovery rate 
test. Unpaired t-test analyses were used for clinical and 
therapy features, and the calculations are shown as mean 
± standard error of the mean. The paired t-test was used 
to compare parameters before and after therapy. P-values 
below 0.05 were considered significant. Cytokines, which 
were significantly different between the asthma clusters, 
were used for principal component analysis to reduce the 
variables to a principal component. Subsequently, receiver 
operating characteristic (ROC) analysis with the identified 
principal component was performed.
cytokine and chemokine measurements
Serum probes from asthma patients were taken upon entry of the 
patients and stored at −80°C until they were analyzed. Serum 
cytokines were quantified by multiplex measurements (Bioplex; 
Bio-Rad Laboratories, Hercules, CA, USA). Of 48 serum 
cytokines or chemokines, 36 were in the detection range in at 
least 50% of the asthma patients and used for analyses.
Results
Classification of asthma patients 
according to markers for clinical  
asthma severity and treatment response
Asthma patients were classified according to Junipers symp-
tom score, FEV
1
, serum ECP, circulating eosinophils, and 
the improvement in FEV
1
, ECP, and circulating eosinophils 
after 3 weeks of therapy in the high-altitude clinic in Davos-
Wolfgang. Using hierarchical cluster analysis, two clusters of 
asthma patients were obtained (Figure 1A). Asthma patients 
in cluster 1 (n=60) had significantly higher Junipers symptom 
scores, lower FEV
1
 values, higher ECP serum levels, and 
a tendency towards higher blood eosinophils than asthma 
patients in cluster 2 (n=131) on the day they arrived in the 
clinic (Figure 1B). The response to asthma therapy dif-
fered between these two groups. Asthma patients in cluster 
1 showed a higher FEV
1
 improvement, blood eosinophil 
decrease, and serum ECP decrease after 3 weeks of intensive 
asthma therapy (Figure 1C).
characterization of asthma patients  
in clusters 1 and 2
Asthma patients in clusters 1 and 2 were further character-
ized by physical examination results, medications, and ques-
tionnaire data. The frequency of asthma patients fulfilling 
American Thoracic Society criteria (for detailed information 
see http://www.thoracic.org) for severe asthma was signifi-
cantly higher in cluster 1 than in cluster 2. The average age 
of patients in cluster 1 was higher (54.4±12.0 years) than of 
those in cluster 2 (48.1±15.9 years), the asthma patients in 
cluster 1 had significantly more asthma exacerbations over 
the previous 12 months and less well controlled asthma. In 
addition, asthma patients in cluster 1 received systemic ste-
roids, β2-mimetics (long and short acting), and theophylline 
as asthma medications more frequently as at the day of entry. 
There was no difference between these two groups in terms 
of age of onset, sex, exposure to cigarette smoke, body mass 
index, serum IgE levels, allergic sensitization, adherence to 
therapy, and therapy with inhaled steroids (see Table 1).
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Figure 1 Classification of asthma patients according to airway inflammation. 
Notes: 191 asthma patients were classified by hierarchical cluster analysis with indicated parameters. (A) Dendrogram. (B) At entry to the high-altitude clinic, FeV1 values, 
ecP and blood eosinophil levels, and Junipers asthma symptom score were evaluated for cluster 1 and 2. (C) changes in FeV1, ecP, and blood eosinophils after 3 weeks of 
asthma therapy from cluster 1 and 2. c1: asthma patients in cluster 1; c2: asthma patients in cluster 2; *P,0.05, ***P,0.001; unpaired t-test was used. 
Abbreviations: ecP, eosinophil cationic protein; FeV1, forced expiratory volume in 1 second; n, number of asthma patients.
To further specify the response to asthma therapy, 
FEV
1
, serum ECP, blood eosinophils, and exhaled NO 
were measured on the day of entry and at discharge after 
3 weeks. FEV
1
 increased significantly from 56.0%±13.6% 
to 66.7%±19.1% in asthma patients belonging to cluster 
1, whereas there was no significant change in FEV
1
 in 
asthma patients in cluster 2 (entry 93.8%±16.3%; discharge 
92.9%±18.2%, Figure 2A). In addition, ECP serum levels 
decreased from 32.3±25.8 µg/L to 19.8±16.2 µg/L in 
asthma patients in cluster 1, whereas they did not change 
for those in cluster 2 (entry 18.7±12.5 µg/L, discharge 
19.4±13.9 µg/L, Figure 2A). Blood eosinophils and exhaled 
NO significantly decreased in both groups after 3 weeks 
of therapy. Concerning asthma medication, there was no 
significant change in systemic steroids, inhaled steroids, 
and long-acting β2 agonists between entry and discharge 
in both clusters, whereas the frequency of short-acting β2 
agonist usage decreased significantly in both groups after 
asthma therapy (Figure 2B).
Taken together, asthma patients in cluster 1 are character-
ized by a less well controlled disease and better response to 
asthma therapy than asthma patients in cluster 2.
Increased serum inflammatory  
protein levels in asthma patients  
between cluster 1 and cluster 2
Next, inflammatory serum protein levels in all asthma 
patients were analyzed. IL-8, eotaxin, VEGF, cutaneous 
T-cell-attracting chemokine (CTACK), growth-related 
oncogene (GRO)-α, and hepatocyte growth factor (HGF) 
in the sera of asthma patients belonging to cluster 1 were 
significantly higher than in patients in cluster 2 (Figure 3A; 
for full names of the following cytokines and chemokines, 
see Table S1). There was no significant difference in IL-1Ra, 
IL-2, -4, -6, -9, -10, -13, -15, -16, -17, -18, IFN-γ, TNF-α, 
MIP-1α, MIP-1β, MIF, MIG, SCF, SCGFβ, G-CSF,  IFN-α, 
LIF, MCP-3, MCSF, FGF, SDF-1α, MCP-1, IP-10, and 
TRAIL levels (see Table S1).
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Figure 2 Asthma patients in cluster 1 respond better to asthma therapy. 
Notes: (A) FeV1, serum ecP levels, blood eosinophil levels and exhaled nO at the beginning of the high altitude stay (entry) and after 3 weeks (discharge). (B) Fraction of 
patients with systemic steroids and inhaled steroids, systemic steroid dose and frequency of inhaled short acting β2 agonist usage. The paired t-test was used to compare 
changes in indicated parameters between entry and discharge. **P,0.01; ***P,0.001. 
Abbreviations: ecP, eosinophil cationic protein; FeV1, forced expiratory volume in 1 second; n, number of asthma patients; nO, nitric oxide.
Principal component analysis of the concentrations of 
all cytokines and chemokines that are upregulated in cluster 
1 was performed. An ROC for the principal component 
revealed a sensitivity of 55.9% and a specificity of 75.8% 
for distinguishing between asthma patients in clusters 1 and 
2 (area under the curve [AUC] 0.683; Figure 4A). The AUC 
for single cytokines was lower than the principal component 
analysis of all upregulated cytokines in cluster 1 (AUC 
IL-8: 0.645; CTACK: 0.639; eotaxin: 0.640; GROα: 0.632; 
HGF: 0.625; VEGF: 0.627; Figure 4B). In addition, there is 
a significant negative correlation between cytokine serum 
levels of the upregulated cytokines in cluster 1 and FEV
1
 
(Figure 4C).
Discussion
Using hierarchical cluster analysis with the clinical routine 
parameters FEV
1
, ECP serum levels, blood eosinophil 
levels, or Junipers asthma symptom score, we were able to 
classify our population of asthma patients into two groups. 
One group of asthma patients (cluster 1) was characterized 
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Figure 3 Upregulation of serum cytokines and chemokines in asthma patients belonging to cluster 1. 
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by higher ECP serum levels, higher numbers of circulat-
ing eosinophils, lower FEV
1
 values, and better response to 
asthma therapy. Further characterization of these asthma 
patients demonstrated that they had less well controlled 
asthma with more exacerbations over the previous year. 
Importantly, these asthma patients had higher serum levels 
of certain pro-inflammatory cytokines and chemokines. In 
addition, the profile of serum cytokines could predict, with 
a sensitivity of 55.9% and specificity of 75.8%, the cluster 
to which asthma patients belonged.
Asthma is a heterogeneous disease, which could be 
divided into subgroups according to therapy response, 
fixed airway obstruction, obesity, or trigger factors such 
as allergens, air pollution, occupational irritants, cigarette 
smoke, aspirin, and exercise.15 The identification of asthma 
phenotype-specific inflammatory pathways is one important 
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approach to improve the diagnosis and treatment of asthma. 
In this context, the term endotype16 was recently introduced, 
which suggests that asthma phenotypes are characterized 
by certain inflammatory mechanisms, which correlate with 
treatment response.1 Accordingly, we classified the asthma 
patients into two groups by parameters used routinely in our 
clinic and that reflected clinical asthma severity and response 
to asthma treatment. Serum cytokine and chemokine levels 
were measured to investigate if different inflammatory path-
ways were activated in asthma patients from clusters 1 and 
2. Interestingly, in asthma patients from cluster 1, higher 
serum levels of IL-8, eotaxin, VEGF, CTACK, GROα, and 
HGF were present, indicating that different inflammatory 
and molecular mechanisms were activated. In addition, 
IL-17 had the tendency to be elevated in cluster 1 compared 
with cluster 2. Serum IL-17 is elevated in severe asthma11 
and amplifies local airway inflammation by induction of 
IL-6 in bronchial epithelial cells17 or IL-8 in human airway 
epithelial cells.18 IL-17 and Th2 cytokine-producing T-cells 
also promote asthmatic inflammation via the upregulation of 
eotaxin in bronchial epithelial cells.19 In addition, in bronchial 
biopsies from asthmatic patients, there is a high expression 
of VEGF,20 which is a key regulator of blood vessel growth 
in the airways of asthma patients via the promotion of prolif-
eration and differentiation of endothelial cells and inducing 
vascular leakage and increased permeability.21 One possible 
explanation for elevated inflammation-related cytokines and 
chemokines in the sera of asthma patients with lower FEV
1
 
values and more frequent exacerbations may be that airway 
inflammation may lead to the generation of large amounts 
of cytokines, which may enter into the circulation, resulting 
in elevated serum concentrations. Therefore, the upregula-
tion of certain cytokines and chemokines in the sera may 
be an indicator for physicians to optimize or initiate asthma 
treatment. Interestingly, asthma patients in cluster 1 and 
2 were all mostly compliant with the medication therapy, 
indicating that the FEV
1
 improvement in asthma patients 
with clinically more severe asthma (cluster 1) might be due 
to treatment optimization and not to an improvement in 
medication compliance.
Although treatment management of asthma patients by 
measurement of sputum eosinophils could decrease the num-
ber of asthma exacerbations and steroid dose,22 eosinophils 
may not be useful in the prediction of exacerbations for all 
asthma types because, besides eosinophilic asthma, neutro-
philic, mixed granulocytic, and paucigranulocytic asthma 
subgroups also exist.23 In addition, the induction of induced 
sputa may not be technically possible in all asthma patients. 
Analysis of serum eosinophils is a simple method that is 
routinely undertaken for asthma patients. However, in our 
study, serum eosinophils were not significantly elevated in 
patients with clinically more severe asthma (cluster 1) in 
contrast with the identified serum proteins, suggesting that 
they are also upregulated in exacerbated non-eosinophilic 
asthma. The higher levels of pro-inflammatory cytokines 
and chemokines in the serum indicate asthma patients 
with poorly controlled asthma. Therefore, measuring 
serum cytokines as a diagnostic tool might be useful for 
the optimization of asthma treatment. However, this study 
has not assessed the direct effect of asthma medications on 
serum cytokines. Therefore, the effect of asthma treatment 
on the serum cytokines upregulated in cluster 1 should be 
investigated in future studies. Less invasive methods for the 
assessment of local airway inflammation include analysis 
of nitrates24 or pH values25 in exhaled breath condensates, 
which are related to asthma control and may be interesting 
tools for asthma management in the future. These methods 
may also be combined with the measurement of serum 
cytokines and chemokines.
Repeated airway inflammation causes structural airway 
changes, known as airway remodeling, including smooth 
muscle hypertrophy, goblet cell hyperplasia, subepithelial 
fibrosis, and angiogenesis.21 These structural changes influ-
ence the reversibility of airway obstruction and increase 
disease severity.26 Inflammatory markers, which can predict 
the severity of airway inflammation, could be important for 
optimal asthma treatment decisions to avoid airway remod-
eling caused by chronic inflammation. We demonstrate that 
certain serum cytokines and chemokines could identify 
asthma patients with clinically more severe asthma and bet-
ter treatment response.
Conclusion
Certain pro-inflammatory serum cytokines and chemokines 
are important markers for the severity and activity of asthma, 
asthma control, and treatment response. The assessment of 
systemic immune response by serum levels of cytokines 
and chemokines in asthma patients might be an important 
tool for monitoring asthma patients and for asthma therapy 
optimization.
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Differential serum protein markers and clinical severity of asthma
Table S1 serum cytokine and chemokine levels in asthma 
patients belonging to cluster 1 or to cluster 2
Cluster 1 Cluster 2 P-value
il-1ra 1,465.7±1,741.6 1,927.3±3,958.4 0.34
il-2 62.8±97.0 90.4±334.3 0.34
il-4 67.9±24.8 63.1±26.9 0.14
il-9 864.1±2,783.0 631.1±3,446.8 0.23
iFn-γ 2,057.1±2,207.5 2,070.8±3,370.4 0.15
MiP-1β 510.5±509.2 1,228.1±858.3 0.19
TnF-α 237.4±217.1 262.8±348.5 0.31
il-2ra 1,016.5±1,140.8 676.4±574.2 0.06
il-18 643.5±361.6 568.9±324.1 0.11
MiF 1,2541.2±7,713.4 10,153.0±5,276.7 0.10
Mig 13,156.3±19,172.1 9,572.8±19,840.7 0.10
scF 894.2±418.2 804.4±326.6 0.21
scgFβ 199,001.3±133,999.6 159,837.8±107,284.1 0.06
g-csF 211.0±213.8 184.0±202.8 0.34
FgF 232.6±262.8 206.6±298.4 0.33
il-6 62.7±70.9 62.5±142.5 0.08
il-10 57.8±291.0 36.2±134.7 0.09
il-15 41.1±62.8 26.9±57.1 0.07
MiP-1α 26.2±25.7 20.3±23.5 0.05
iFn-α 39.8±116.7 18.5±65.4 0.16
liF 86.7±557.1 12.5±27.9 0.36
McP-3 146.4±956.3 47.9±154.1 0.83
McsF 27.6±61.0 22.0±58.3 0.32
sDF-1α 189.1±315.1 151.6±264.9 0.52
il-13 43.9±87.9 36.2±75.5 0.06
Notes: Serum levels of cytokines and chemokines, which were not significantly 
different between cluster 1 and cluster 2 are shown. Mann–Whitney U test was 
used. concentrations are shown in pg/ml ± sD.
Abbreviations: il, interleukin; iFn-γ, gamma-interferon; MiP-1β, macrophage 
inflammatory protein 1 beta; TNF-α, tumor necrosis factor-alpha; MiF, macrophage 
migration inhibitory factor; Mig, monokine-induced by interferon-gamma; scF, 
stem cell factor; scgFβ, stem cell growth factor beta; g-csF, granulocyte colony-
stimulating factor; FGF, fibroblast growth factor; MIP-1α, macrophage inflammatory 
protein 1 alpha; iFn-α, alpha-interferon; liF, leukemia inhibitory factor; McP-3, 
monocyte chemotactic protein-3; McsF, macrophage colony-stimulating factor; 
sDF-1α, stromal cell-derived factor-1 alpha; sD, standard deviation.
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